Compass Pathways

Compass Pathways is a UK-based mental health company developing COMP360, a proprietary synthetic psilocybin formulation administered with psychological support. Among public psychedelic companies, it remains one of the clearest tests of whether a psilocybin program can move through late-stage development with regulator-facing rigor and enough evidence to matter commercially.

TRD program

The company’s investor materials describe COMP360 as a Breakthrough Therapy-designated program for treatment-resistant depression and frame its Phase 3 effort as the largest randomized, controlled, double-blind psilocybin-treatment program yet run. That matters because Compass is no longer just a concept-stock proxy for psychedelic optimism, it is running the kind of pivotal program that investors, regulators, and skeptics will all use as a reference point.

Public registry records also now anchor the program to concrete trial IDs, including NCT05624268 and NCT05711940, rather than only to company narrative. That strengthens the trust surface around the dossier because the clinical path can be checked independently.

PTSD expansion

In January 2026, Compass said the FDA had authorized an IND application to initiate a Phase 3 PTSD program around COMP360. Even before any approval outcome, that step signals that the company is trying to widen beyond TRD while staying inside formal FDA pathways.

Why this page matters

Compass is one of the few psychedelic companies that still sits at the intersection of official regulator engagement, large late-stage trials, and a recognizable public market story. If COMP360 succeeds, it becomes a major validation point for the category; if it fails, that failure will shape how the next wave of psychedelic programs gets judged.